Table 4.
Patient characteristics (patched-pair)
| ICBT (n = 160) | HBT (n = 160) | P-value | ||
|---|---|---|---|---|
| Age (median), years | 57 (28-86) | 58 (26-81) | 0.942 | |
| Follow-up period (median), months | 50.8 (5.2-138.4) | 45.5 (3.0-105.3) | <0.001* | |
| FIGO stage (2008) | ||||
| IB2-II | 73 (45.6%) | 72 (45%) | 1 | |
| III-IVA | 87 (54.4%) | 88 (55%) | ||
| Histological subtypes | ||||
| Squamous cell carcinoma | 149 (93.1%) | 150 (93.8%) | 0.226 | |
| Adenocarcinoma | 6 (3.8%) | 9 (5.6%) | ||
| Adenosquamous carcinoma | 5 (3.1%) | 1 (0.6%) | ||
| Uterine body invasion | ||||
| Yes | 59 (36.9%) | 77 (48.1%) | 0.054 | |
| No | 101 (63.1%) | 83 (51.9%) | ||
| Pyometra | ||||
| Yes | 45 (28.1%) | 35 (21.9%) | 0.198 | |
| No | 115 (71.9%) | 125 (78.1%) | ||
| Parametrium invasion | ||||
| Yes | 148 (92.5%) | 143 (89.4%) | 0.223 | |
| No | 12 (7.5%) | 17 (10.6%) | ||
| Hydronephrosis | ||||
| Yes | 33 (20.6%) | 40 (25%) | 0.221 | |
| No | 127 (79.4%) | 120 (75%) | ||
| Pelvic LN metastasis | ||||
| Yes | 89 (55.6%) | 88 (55%) | 1 | |
| No | 71 (44.4%) | 72 (45%) | ||
| Tumor size at diagnosis (median, cm) | 5.9 (4.0-12) | 5.7 (4.1-11) | 0.835 | |
| Tumor size before brachytherapy (median, cm) | 4.1 (1.6-6.6) | 4.1 (2.0-9.0) | 0.087 | |
| Reduction ratio (%) | 29 (0-74) | 28 (0-71) | 0.084 | |
| Total treatment time (median, weeks) | 7 (5-11) | 7 (5-14) | 0.914 | |
FIGO: the International Federation of Gynecology and Obstetrics
LN: lymph node
ICBT: intracavitary brachytherapy
HBT: hybrid brachytherapy
*Statistical significance was defined as a P-value of <0.05.